© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
April 13, 2022
Dave Dixon, PharmD, discussed heart failure treatments in the pipeline and what he sees for the future of pharmacists in cardiovascular care.
April 04, 2022
With therapeutics developing quickly in the cardiovascular space, pharmacists are more important than ever.
Pharmacy Times spoke with Dave Dixon, PharmD, to learn more about his presentation titled “New Pharmacologic Therapies for Heart Failure.
Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Session at American College of Cardiology Scientific Sessions 2022 highlight treatments for symptomatic obstructive hypertrophic cardiomyopathy.
April 03, 2022
Mark Svet, MD, is the lead study author on a sub-analysis of the VOYAGER PAD study evaluating data on the use of rivaroxaban in patients with peripheral artery disease (PAD) and chronic kidney disease (CKD).
Multiple approaches can be taken to optimize medical therapy in patients with PAD.
Pharmacy Times spoke with Dipti Itchhaporia, MD, the 70th president of the American College of Cardiology (ACC).
Despite the approval of exciting new therapies for heart failure, there are still some challenges that need to be addressed to improve patient outcomes.
Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment.